Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to assess the role of AMH in prediction of poor ovarian response as well as the relation between ESR2 (+1730G>A) (rs4986938), FSHR p.Thr307Ala (c.919A>G, rs6165) and FSHR p.Asn680Ser (c.2039A>G, rs6166) SNPs and the poor response in Egyptian women undergoing IVF procedure. Discovering the genetic variants associated with ovarian response is an important step towards individualized pharmacogenetic protocols of ovarian stimulation.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Cetrorelix; Chorionic Gonadotropin; Hormones; Menotropins

Criteria

Inclusion Criteria:

• Women at or under the age of 35 years.

• Normal thyroid stimulating hormone and prolactin levels.

• Normal ovulatory cycles (25-35 interval days), together with proven patent fallopian tubes at hysterosalpingography or laparoscopy done within six cycles preceding the ICSI cycle.

• Presence of both ovaries with normal findings as assessed by trans-vaginal ultrasound and laparoscopy.

• All male partners had a normal semen analysis according to WHO criteria (WHO, 2010), done within 6 months preceding the ICSI cycle

Exclusion Criteria

• Chronic medical disorders such as diabetes.

• Previous inadequate response to ovulation induction.

• Polycystic ovary syndrome.

• Women who performed ovarian surgery and cases of endometriosis diagnosed by laparoscopy or suspected by ultrasound or CA-125 assay.

• Abnormal pelvic pathology or congenital anomalies.